Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00344305 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT00344305 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 200 participants.
The verdict
NCT00344305, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
Open label, single arm, multicenter study of the shedding and safety of a single dose of trivalent, influenza virus vaccine live, intranasal in children 6 to \< 60 months of age, with 28-day shedding follow-up and 180-day safety follow-up.
Interventions
- BIOLOGICAL Trivalent influenza virus vaccine live, intranasal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-05-01 |
| Est. Completion | 2006-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00344305
The ClinicalTrials.gov registry entry for NCT00344305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trivalent influenza virus vaccine live, intranasal is the first listed.
NCT00344305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00344305 about?
NCT00344305 is a clinical study titled "A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children". Open label, single arm, multicenter study of the shedding and safety of a single dose of trivalent, influenza virus vaccine live, intranasal in children 6 to \< 60 months of age, with 28-day shedding follow-up and 180-day safety follow-up.
What is the current status of trial NCT00344305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2006-05-01. Estimated completion is 2006-12-01.
What interventions are being tested in trial NCT00344305?
The interventions under investigation include: Trivalent influenza virus vaccine live, intranasal (BIOLOGICAL).
Who is sponsoring clinical trial NCT00344305?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.